The mean number of injections given increased only modestly in groups with more active lesions (7.6, 7.9, 8.4, 8.3 respectively, P=0.015). Occult and minimally classic lesions were more frequent in the more active groups (P=0.024).
INTRODUCTION
Despite the remarkable efficacy of Vascular Endothelial Growth Factor (VEGF) inhibitors for neovascular Age-related Macular Degeneration (wet AMD) [1] [2] [3] , there is still no consensus on how they are used most effectively. Monthly, pro re nata (PRN) 4 and "treat and extend" 5 are commonly used treatment regimens for wet AMD. An underlying principle of all treatments is that lesions with evidence of activity warrant further treatment 6 .
One of the leading indicators of persistent activity of choroidal neovascularization (CNV) is the presence of sub-or intra-retinal fluid. Previous experience with other conditions, particularly idiopathic central serous chorioretinopathy, suggests that the presence of subretinal fluid is eventually associated with progressive loss of vision which is thought to be secondary to the detachment of neuroretinal tissue from the retinal pigment epithelium 7 . Similarly, photoreceptor apoptosis has been described in rhegmatogenous retinal detachments in humans and animal models 8 9 . Persistent intraretinal fluid accumulation -typically seen in macular edema such as in uveitis or post-cataract surgery -has been proposed to result in lasting damage to retinal cells, eventually leading to fibrosis and atrophy of the neuroretinal tissue, 10 thereby damaging vision irreversibly.
Persistently active CNVs, as evidenced by intra-or subretinal fluid, in eyes with AMD that are receiving regular treatment with anti-VEGF agents are commonly found in clinical practice. In the Comparison of AMD Treatment Trials (CATT) study, for example, the proportion of eyes with sub-or intra-retinal fluid ranged from 86.1% in the bevacizumab (Avastin) as needed group to 54.5% in the ranibizumab (Lucentis) monthly group after 2 years of treatment 2 . Strategies that have been proposed for eyes with persistent activity despite 4 weekly anti-VEGF therapy include injection of larger doses 11 12 , 2-weekly injections 13 or combination with other agents 14 15 . Few data are available on the course of such lesions, however, to determine if these maneuvers are necessary.
Since are few good data are available from clinical trials in which independent
Reading Centre adjudication of lesion activity has been correlated with outcomes, analysis of registry data can be performed to study this point in real world practice in which judgments are made by the treating clinician. Here we describe characteristics and clinical course of eyes of participants in an outcomes registry 16 with wet AMD receiving injections of anti-VEGF drugs as a function of their CNV activity status.
METHODS

Design
This observational study used anonymized longitudinal data from the FRB! Project's audit on eyes treated for wet AMD. The concepts of the FRB! system and the wet AMD audit have already been published 16 17 . Briefly, anonymized data of patients treated for wet AMD were captured during routine clinical practice. Treatment decisions and visit schedules were made at the treating physician's discretion. This research project adheres to the Tenets of the Declaration of Helsinki. Ethics approval was obtained from the respective ethic committees by each participating center.
Patients were given information about the project and were given the option to opt out of the audit in which their data were anonymized. Participating centers located in Australia, New Zealand and Switzerland contributed data.
Patient selection and variables
Treatment-naïve eyes with at least 12 months of follow-up were identified from the FRB! Project's wet AMD audit. Only eyes with at least 2 injections of ranibizumab and a maximum time between two consecutive visits of 150 days were included. In cases where both eyes from one participant were included, one was randomly deleted from the analysis set to ensure any inter-eye correlation would not bias estimates. 
Primary outcome
The primary outcome was change of VA in logMAR letters 12 months after the index visit within each of the four groups. For each eye the proportion of times over the 12 months of treatment at which the lesion was graded "active" was calculated. Four groups were formed and ranked in order of activity: "Persistent", "High", "Moderate"
and "Low". Persistent activity was defined as activity at all visits. The cut points to form the other 3 groups were chosen to be at activity levels which would divide the remaining eyes into equally sized groups.
Secondary outcomes
Secondary outcomes included the number of injections received during 12 months and reported adverse events.
Statistics
Descriptive statistics for continuous variables included mean, median and first and third quartiles (Q1 & Q3). Where appropriate, continuous data were summarized with boxplots where the whisker length is either 1.5 times the interquartile range or the most extreme value (whichever is smaller). Categorical variables were summarized as percentages; any eyes with missing data were excluded from the denominator and formal comparisons were made with the chi-squared test.
An ordered logistic regression model 18 was fitted to the data with age, index VA, lesion type and GLD as predictor variables for the ordinal activity group variable. Approximately 30% (n=196) of all available eyes were consistently graded active over 12 months' treatment, these formed the Persistent activity group (Table 1) . Eyes classified as active for between 58% and 99% of the time formed the High activity group (n=152, 23%), those active between 27% and 57% formed the Moderate activity group (n= 154, 24%) and the remainder formed the Low activity group (n=153, 23%).
Index visit data
Mean patient age was similar across groups with an overall mean of 79.4 years, as was the proportion of females (overall 61.4%) ( Table 1) . Mean index visual acuity was remarkably similar amongst the four groups (overall mean 54.9). The distribution of lesion types varied significantly across the four groups (P = 0.02; χ²=23.5, 12 df).
OC and MC lesions were increasingly frequent in the more active groups (Table 1 ).
There was a small but significant trend of increasing activity with increasing GLD (linear correlation = 0.17, 95% CI: 0.09 to 0.26).
The observed differences in mean GLD per group may be a result of the different lesion type makeup of each group (Table 1) . In order to further examine the relative associations of lesion type and GLD to lesion activity independent of one another, an ordered logistic regression model was fitted to the data. (Table 2) . Each group had statistically significantly improved VA at 12 months compared with the index visit (p<0.001).
Secondary outcomes -Treatment intensity
Early treatment, as measured by time to the 3rd injection in each group was consistent ( Table 2 ). The mean number of intravitreal injections administered over 12 months increased modestly with increasing lesion activity (P=0.0151, Poisson regression; Table 2 Twelve-month improvements in VA did not change markedly over time (2007) (2008) (2009) (2010) (2011) in any group (Fig 3) . 
Secondary outcomes -Safety
Adverse events reported during 12 months' treatment are shown in 
Discussion
We have analyzed outcomes of eyes treated for neovascular AMD according to the surgeon's grading of neovascular lesion activity over 12 months after commencing treatment with intravitreal ranibizumab. Interestingly, eyes with lesions that were graded by the treating surgeon as being active at most visits had similar 12-month VA outcomes to those with less active lesions. Chronically active lesions were generally larger and more likely to be occult in nature, yet all activity groups studied showed a clear improvement in mean VA over 12 months. Ocular adverse events were uncommon and similar to data published previously 21 .
The analysis of observational study data has strengths and weaknesses compared with data from RCTs, which are the source of information upon which clinical decisions are usually made, at least in this field. Observational studies lack a strict protocol for re-treatment, with potential for considerable variation in treatment practices among the 27 clinicians involved. All 27 participating ophthalmologists stated that they used a "treat and extend" treatment regimen. The advantage of observational studies is they tell us how treatments are given in routine practice, in this case how clinicians interpret lesion activity and the effect this has on number of injections required and the VA outcome.
Although it might be expected that eyes with chronically active lesions would have less favorable VA outcomes due to progressive structural damage of the outer retina, we did not find this. Outcomes were similar among the four groups ranked for degree of activity. One reason contributing to this may be the higher proportion of occult lesions in the more active groups, since it has been reported that untreated occult-only lesions have a more favorable outcome than lesions with classic components, 21 possibly because they cause less structural damage of the neural retina. The CATT study reported that lesions with a classic component were likely to result in less favorable VA outcomes at 12 months. 22 There were higher proportions of occult membranes in the more active groups. While this may seem counter-intuitive, occult membranes have not penetrated the Retinal Pigment Epithelium 23 , the site of the outer blood-retinal barrier, whereas most classic neovascular complexes have 24 .
Thus an intravitreally injected drug may reach classic neovascularization at higher levels than it does for occult membranes, which may therefore be less responsive to the same treatment. In conclusion, we found that lesion activity as assessed by the treating physician had less effect on visual acuity outcomes from intravitreal therapy for neovascular AMD than expected. It is important to note that the data presented were collected at a time when clinicians generally agreed that the goal of treatment was to render lesions inactive. Treating persistently active lesions less aggressively might result in inferior outcomes. If our results are replicated by other studies, perhaps there may be less emphasis on using higher doses or treating persistently active lesions more frequently.
Further research is warranted to determine outcomes when physicians place less emphasis on lesion activity as an indication for treatment. indicates the eye was graded "active" while a green dot represents "inactive" status.
The Loess line fitted to the data elucidates group changes in VA over time. 
